Vertex scores FDA nod for kids’ cystic fibrosis drug Trikafta
Trikafta was approved by FDA for the treatment of Cystic Fibrosis in patients aged 6 to 11 years, after receiving approval to be used in patients of ages 12 and up. The FDA has authorized Vertex...
View ArticleActivist investor Elliott Management asks for new board and CEO to reapply
Before the splitting of GlaxoSmithKline’s consumer healthcare sector next year, Elliot Management, an activist US investor, has effectively requested that Dame Emma Walmsley should apply again for her...
View ArticleRoche to lay off 300 to 400 employees in product development jobs
Roche’s executives, including CMO (Chief Medical Officer) Levi Garraway, claimed in a recorded video conference with staff acquired by Swiss Newspaper Blick, that the company is planning to slash 300...
View ArticlePharma manufacturers lawsuits against payers and benefit managers preferred...
The attention of federal antitrust regulators has been drawn to a slew of lawsuits filed by pharmaceutical companies, challenging the “preferred” medicine list of payers and benefit managers. Pfizer,...
View ArticleNRx Pharmaceuticals signs deal for clinical trials of Israel’s homegrown...
Israel Institute for Biological Research (IIBR), an institute run by Israel’s Defense Ministry, has signed a memorandum of understanding (MoU) with the NRx Pharmaceuticals. According to which Israel’s...
View ArticleAstraZeneca and FibroGen hit FDA committee’s safety data firewall for roxadustat
Two roxadustat partners AstraZeneca and FibroGen have received objections regarding safety concerns of their drug from the FDA after which the two companies headed into a high-stakes meeting with the...
View ArticleIs Biogen’s Alzheimer’s drug worth $56K? Experts say $8400 and raise...
Aduhelm, Biogen’s new drug for Alzheimer’s disease, which was approved by FDA contentiously last month, continues to face criticism since then. The FDA now says it should be investigated...
View ArticleSanofi to acquire Origimm Biotechnology in a bid to expand vaccine pipeline
Sanofi will acquire Origimm Biotechnology as per an agreement signed by the two healthcare companies. The deal is expected to be finalized within the month but has not revealed any financials, so far....
View ArticleAussie pharma CSL in talks to buy Swiss firm Vifor Pharma for USD 7B
CSL, the Australian giant, is in talks to buy Vifor Pharma in a deal that is valued at $7B, or A$10B. Vifor Pharma is a Swiss pharma company.Analysts predict that as CSL buys Vifor Pharma it will be...
View ArticleChina forces insulin price cuts resulting in pullback for global pharma players
Xinhua, a Chinese news channel, commented on the price cut on insulin which was brought on by China’s volume-based procurement (VBP) program. An over 45% discount on insulin products had to be given...
View Article
